Compare TALO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TALO | RAPP |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2017 | 2024 |
| Metric | TALO | RAPP |
|---|---|---|
| Price | $16.65 | $33.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $19.89 | ★ $62.88 |
| AVG Volume (30 Days) | ★ 1.7M | 403.7K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,780,070,000.00 | N/A |
| Revenue This Year | $26.70 | N/A |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.97 | $23.75 |
| 52 Week High | $18.73 | $52.93 |
| Indicator | TALO | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 29.65 |
| Support Level | $16.01 | $33.15 |
| Resistance Level | $17.23 | $40.61 |
| Average True Range (ATR) | 0.56 | 2.53 |
| MACD | -0.16 | -0.75 |
| Stochastic Oscillator | 10.26 | 19.11 |
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.